JP2005516986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516986A5 JP2005516986A5 JP2003565415A JP2003565415A JP2005516986A5 JP 2005516986 A5 JP2005516986 A5 JP 2005516986A5 JP 2003565415 A JP2003565415 A JP 2003565415A JP 2003565415 A JP2003565415 A JP 2003565415A JP 2005516986 A5 JP2005516986 A5 JP 2005516986A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- amino
- oxime
- carbonyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 dibenzofuranyl Chemical group 0.000 claims 49
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 49
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 47
- 150000002923 oximes Chemical class 0.000 claims 47
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 125000001475 halogen functional group Chemical group 0.000 claims 17
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 12
- 239000002671 adjuvant Substances 0.000 claims 12
- 239000003085 diluting agent Substances 0.000 claims 12
- 239000003937 drug carrier Substances 0.000 claims 11
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 claims 2
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 2
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 claims 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- QJLORVSDABTRCS-UHFFFAOYSA-N phenyl n-(4-undecoxyphenyl)carbamate Chemical compound C1=CC(OCCCCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1 QJLORVSDABTRCS-UHFFFAOYSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- OHKUODJKULFCPB-UHFFFAOYSA-N (2,4-difluorophenyl) n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=C(F)C=C1F OHKUODJKULFCPB-UHFFFAOYSA-N 0.000 claims 1
- PWZMFAZZDZNTOQ-UHFFFAOYSA-N (2-fluorophenyl) n-(4-decoxyphenyl)carbamate Chemical compound C1=CC(OCCCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1F PWZMFAZZDZNTOQ-UHFFFAOYSA-N 0.000 claims 1
- PHBVHSXINCCZDW-UHFFFAOYSA-N (2-fluorophenyl) n-(4-octoxyphenyl)carbamate Chemical group C1=CC(OCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1F PHBVHSXINCCZDW-UHFFFAOYSA-N 0.000 claims 1
- XSSVFUMMMRTXER-UHFFFAOYSA-N (2-fluorophenyl) n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=CC=C1F XSSVFUMMMRTXER-UHFFFAOYSA-N 0.000 claims 1
- GDLJXVIFSNBWKP-UHFFFAOYSA-N (2-fluorophenyl) n-[1-(4-butoxyphenyl)propyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1C(CC)NC(=O)OC1=CC=CC=C1F GDLJXVIFSNBWKP-UHFFFAOYSA-N 0.000 claims 1
- RFAALCRYXIMHGO-UHFFFAOYSA-N (3-chlorophenyl) n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=CC(Cl)=C1 RFAALCRYXIMHGO-UHFFFAOYSA-N 0.000 claims 1
- BVPXJSVMJYBIRX-UHFFFAOYSA-N (4-fluorophenyl) n-[(4-butoxyphenyl)methyl]carbamate Chemical group C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=C(F)C=C1 BVPXJSVMJYBIRX-UHFFFAOYSA-N 0.000 claims 1
- IEKBPHHXDXKATO-UHFFFAOYSA-N (4-fluorophenyl) n-[1-(4-butoxyphenyl)propyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1C(CC)NC(=O)OC1=CC=C(F)C=C1 IEKBPHHXDXKATO-UHFFFAOYSA-N 0.000 claims 1
- LCRIEQJXNHPILH-UHFFFAOYSA-N (4-methoxyphenyl) n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=C(OC)C=C1 LCRIEQJXNHPILH-UHFFFAOYSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- WDBAXYQUOZDFOJ-UHFFFAOYSA-N 2,3-difluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1F WDBAXYQUOZDFOJ-UHFFFAOYSA-N 0.000 claims 1
- CYIFJRXFYSUBFW-UHFFFAOYSA-N 2,4,5-trifluorobenzaldehyde Chemical compound FC1=CC(F)=C(C=O)C=C1F CYIFJRXFYSUBFW-UHFFFAOYSA-N 0.000 claims 1
- SOWRUJSGHKNOKN-UHFFFAOYSA-N 2,6-difluorobenzaldehyde Chemical compound FC1=CC=CC(F)=C1C=O SOWRUJSGHKNOKN-UHFFFAOYSA-N 0.000 claims 1
- XDMZVNQKVMTCSP-UHFFFAOYSA-N 2-fluoro-3-(trifluoromethyl)benzaldehyde Chemical compound FC1=C(C=O)C=CC=C1C(F)(F)F XDMZVNQKVMTCSP-UHFFFAOYSA-N 0.000 claims 1
- IDLNLGMUINCSGS-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)benzaldehyde Chemical compound FC1=CC=C(C(F)(F)F)C=C1C=O IDLNLGMUINCSGS-UHFFFAOYSA-N 0.000 claims 1
- JPHKMYXKNKLNDF-UHFFFAOYSA-N 3,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1F JPHKMYXKNKLNDF-UHFFFAOYSA-N 0.000 claims 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 claims 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000004634 feeding behavior Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- ZNJJGGVTHHJCRN-UHFFFAOYSA-N phenyl n-(4-decoxyphenyl)carbamate Chemical group C1=CC(OCCCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1 ZNJJGGVTHHJCRN-UHFFFAOYSA-N 0.000 claims 1
- DFYYHKJFWVSJHM-UHFFFAOYSA-N phenyl n-(4-dodecoxyphenyl)carbamate Chemical group C1=CC(OCCCCCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1 DFYYHKJFWVSJHM-UHFFFAOYSA-N 0.000 claims 1
- JPIYDITTWBUFSY-UHFFFAOYSA-N phenyl n-(4-heptoxyphenyl)carbamate Chemical group C1=CC(OCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1 JPIYDITTWBUFSY-UHFFFAOYSA-N 0.000 claims 1
- IJCMIOMSKCNMQY-UHFFFAOYSA-N phenyl n-(4-octoxyphenyl)carbamate Chemical group C1=CC(OCCCCCCCC)=CC=C1NC(=O)OC1=CC=CC=C1 IJCMIOMSKCNMQY-UHFFFAOYSA-N 0.000 claims 1
- ZUXSLOOOUXPMLR-UHFFFAOYSA-N phenyl n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=CC=C1 ZUXSLOOOUXPMLR-UHFFFAOYSA-N 0.000 claims 1
- RENASMKOGKEGAN-UHFFFAOYSA-N quinolin-6-yl n-[(4-butoxyphenyl)methyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1CNC(=O)OC1=CC=C(N=CC=C2)C2=C1 RENASMKOGKEGAN-UHFFFAOYSA-N 0.000 claims 1
- GNIJWICZUOBESL-UHFFFAOYSA-N quinolin-6-yl n-[1-(4-butoxyphenyl)propyl]carbamate Chemical compound C1=CC(OCCCC)=CC=C1C(CC)NC(=O)OC1=CC=C(N=CC=C2)C2=C1 GNIJWICZUOBESL-UHFFFAOYSA-N 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35530202P | 2002-02-08 | 2002-02-08 | |
| PCT/US2003/003222 WO2003065989A2 (en) | 2002-02-08 | 2003-02-04 | (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516986A JP2005516986A (ja) | 2005-06-09 |
| JP2005516986A5 true JP2005516986A5 (https=) | 2006-02-02 |
Family
ID=27734499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565415A Withdrawn JP2005516986A (ja) | 2002-02-08 | 2003-02-04 | （オキシム）カルバモイル脂肪酸アミド加水分解酵素インヒビター |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6949574B2 (https=) |
| EP (1) | EP1472215A4 (https=) |
| JP (1) | JP2005516986A (https=) |
| AU (1) | AU2003210824A1 (https=) |
| PL (1) | PL373970A1 (https=) |
| WO (1) | WO2003065989A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002338329B2 (en) | 2001-03-27 | 2006-09-07 | The Regents Of The University Of California | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
| US20050054730A1 (en) * | 2001-03-27 | 2005-03-10 | The Regents Of The University Of California | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha |
| AU2002311784B2 (en) * | 2001-03-29 | 2007-11-22 | Michael Davis | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| EP1558591B1 (en) | 2002-10-07 | 2014-05-07 | The Regents of The University of California | Modulation of anxiety through blockade of anandamide hydrolysis |
| US7765162B2 (en) * | 2002-10-07 | 2010-07-27 | Mastercard International Incorporated | Method and system for conducting off-line and on-line pre-authorized payment transactions |
| FR2850377B1 (fr) * | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2860514A1 (fr) * | 2003-10-03 | 2005-04-08 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| JP2007509066A (ja) * | 2003-10-16 | 2007-04-12 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 体脂肪を減らし、食欲を抑制し、脂肪酸代謝を調節するための食物および他の組成物、化合物ならびに方法 |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866885B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
| US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| AR055831A1 (es) | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
| ES2528674T3 (es) | 2005-02-17 | 2015-02-11 | Astellas Pharma Inc. | Piperidina y carboxilatos de piperacina como inhibidores de FAAH |
| WO2006116773A2 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of California | Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders |
| EP1954137A4 (en) * | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
| US20070155707A1 (en) * | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
| US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| US20080119549A1 (en) * | 2006-11-20 | 2008-05-22 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| CA2679741A1 (en) * | 2007-03-15 | 2008-09-18 | Sun Pharma Advanced Research Company Ltd. | Novel prodrugs |
| ES2575954T3 (es) * | 2007-10-11 | 2016-07-04 | The Regents Of The University Of California | Composiciones y métodos de inhibición de la amidasa ácida hidrolizante de la N-aciletanolamina |
| EP2062578A1 (en) * | 2007-11-12 | 2009-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel use of chemical compounds for the treatment of AIDS |
| TW201006791A (en) * | 2008-05-15 | 2010-02-16 | Sigma Tau Ind Farmaceuti | Oxime carbamoyl derivatives as modulators of fatty acid amide hydrolase |
| US8207226B1 (en) | 2008-06-03 | 2012-06-26 | Alcon Research, Ltd. | Use of FAAH antagonists for treating dry eye and ocular pain |
| TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| MX2011004704A (es) | 2008-11-06 | 2011-05-30 | Astellas Pharma Inc | Compuesto de carbamato o sal del mismo. |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| EP2632912A4 (en) * | 2010-10-28 | 2014-05-07 | Scripps Research Inst | ANTI-CANCER-SERINHYDROLASE-INHIBITING CARBAMATE |
| AU2012340519B2 (en) | 2011-11-22 | 2017-09-14 | Fondazione Istituto Italiano Di Tecnologia | Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA) |
| EP2931291B1 (en) | 2012-12-11 | 2021-10-20 | The McLean Hospital Corporation | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders |
| US9474271B2 (en) | 2013-01-18 | 2016-10-25 | Research Foundation Of The City University Of New York | Method for enhancing amidohydrolase activity of fatty acid amide hydrolase |
| WO2014144836A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
| WO2014144547A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
| CN105418460B (zh) * | 2014-08-11 | 2017-04-12 | 苏州鹏旭医药科技有限公司 | 匹莫范色林及其类似化合物中间体，其制备方法和制备匹莫范色林及其类似化合物的方法 |
| JP7200261B2 (ja) * | 2017-12-05 | 2023-01-06 | スージョウ ポンシュー ファーマテック カンパニー リミテッド | エラゴリクスを作製するプロセス |
| US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB841141A (en) * | 1955-08-29 | 1960-07-13 | Union Carbide Corp | Naphthyl esters of n-alkyl-substituted carbamic acids and insecticidal compositions containing the same |
| NL302370A (https=) * | 1962-12-22 | |||
| DE1232947B (de) * | 1963-12-09 | 1967-01-26 | Fahlberg List Chemische Veb | Verfahren zur Herstellung von Ketoximcarbanilaten aus Ketoximen und Arylisocyanaten |
| WO1990001874A1 (en) * | 1988-08-24 | 1990-03-08 | Teijin Limited | Oxime derivatives and herbicides containing the same as an active ingredient |
| GB9719530D0 (en) * | 1997-09-12 | 1997-11-19 | Smithkline Beecham Plc | Novel compounds |
| MXPA03009850A (es) * | 2001-04-27 | 2004-02-12 | Bristol Myers Squibb Co | Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso. |
-
2003
- 2003-02-04 US US10/357,807 patent/US6949574B2/en not_active Expired - Lifetime
- 2003-02-04 PL PL03373970A patent/PL373970A1/xx unknown
- 2003-02-04 JP JP2003565415A patent/JP2005516986A/ja not_active Withdrawn
- 2003-02-04 WO PCT/US2003/003222 patent/WO2003065989A2/en not_active Ceased
- 2003-02-04 EP EP03737600A patent/EP1472215A4/en not_active Withdrawn
- 2003-02-04 AU AU2003210824A patent/AU2003210824A1/en not_active Abandoned
-
2005
- 2005-01-19 US US11/039,516 patent/US20050131032A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516986A5 (https=) | ||
| KR100889116B1 (ko) | 이소인돌-이미드 화합물 | |
| JP4896518B2 (ja) | ニコチンアミド系キナーゼ阻害薬 | |
| JP5253696B2 (ja) | 抗腫瘍作用を有するインドリル−３−グリオキシル酸誘導体 | |
| JP2005516986A (ja) | （オキシム）カルバモイル脂肪酸アミド加水分解酵素インヒビター | |
| CN108698991B (zh) | 2-氧代吲哚化合物 | |
| JPH08504435A (ja) | タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン | |
| JP2006514626A5 (https=) | ||
| RU2006109108A (ru) | Соединения, обладающие активностью антагонистов crth2 рецепторов | |
| WO2000076984A3 (en) | Novel compounds, their use and preparation | |
| JP2003500403A5 (https=) | ||
| US20080032965A1 (en) | Method for enhancing cognitive function | |
| AU2019263176A1 (en) | Compounds for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | |
| JP2006500403A (ja) | キノリルプロピルピペリジン誘導体およびその抗菌性物質としての使用 | |
| JPH07509219A (ja) | Ｈ↓３受容体アンタゴニストとしての４−［４’−ピペリジニルまたは３’−ピロリジニル］置換イミダゾールおよび治療上のその使用方法 | |
| JP2002030084A5 (https=) | ||
| CN1268122A (zh) | 用作nos抑制剂的支化烷氧基取代的2－氨基吡啶 | |
| JP2002544193A (ja) | Ｐｄｅ４阻害薬としてのヘテロ置換ピリジン誘導体 | |
| AU681601B2 (en) | O-aryl ethers of morphinans | |
| JP2846895B2 (ja) | 抗痙攣用または神経保護用医薬 | |
| JP2008508251A5 (https=) | ||
| JP2001515509A (ja) | 新規キノリン−およびナフタレンカルボキサミド、医薬組成物およびカルパインの阻害方法 | |
| JP2005517634A5 (https=) | ||
| KR101160858B1 (ko) | 소양 치료약으로서 유용한 4-(2-푸로일)아미노피페리딘류 | |
| JP2005508290A5 (https=) |